Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)

DRUG2 trials

Sponsors

GlaxoSmithKline

Conditions

Carcinoma, Renal Cell

Unknown Phase

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)

CompletedNCT01381601

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2011-03-31End: 2011-10-31Updated: 2013-05-13

Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS)

CompletedNCT01381614

GlaxoSmithKlineCarcinoma, Renal Cell

Start: 2011-03-31End: 2011-12-31Updated: 2013-05-13